eXoZymes Inc. (EXOZ)
NASDAQ: EXOZHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EXOZ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $27.42M
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- 52-week range
- 2.81 – 16.16
- Day range
- 2.84 – 3.31
- Volume / Avg
- 10.82K / 10.14K
- Beta
- —
- Shares outstanding
- 9.44M
52-week range
EXOZ stock today
eXoZymes (EXOZ) closed at $2.91 on Nov 20, down 14.05% (-$0.475), versus the S&P 500's 3.70% decline. At this level, EXOZ sits near the bottom of its 52-week range of $2.81 to $16.16: 82.0% below the high and 3.4% above the low. EXOZ is down 73.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.8%.
eXoZymes has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About eXoZymes
Company profileeXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Michael Heltzen
- Headquarters
- Monrovia, CA
- Employees
- 32
- IPO year
- 2024
- Website
- exozymes.com
Financial highlights
Full financialseXoZymes reported a net loss of $9.2 million, compared with a loss of $5.9 million a year earlier. Diluted earnings per share came in at -$1.09.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | $70.07K |
| Growth | — | — | — |
| Net income | $-9.16M | $-5.86M | $-2.04M |
| EPS (diluted) | $-1.09 | $-0.89 | $-0.33 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.24 vs —
eXoZymes peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs EXOZ |
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs EXOZ |
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs EXOZ |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs EXOZ |
| KLRSKalaris Therapeutics Inc. | 1.28 | -5.19% | $30.47M | vs EXOZ |
| CRBUCaribou Biosciences Inc. | 0.2843 | -8.44% | $30.71M | vs EXOZ |
| MGXMetagenomi Therapeutics Inc. | 0.565 | -7.95% | $21.36M | vs EXOZ |
| CVMCel-Sci Corporation | 1.21 | -17.69% | $21.28M | vs EXOZ |
Indexes, lists and sector
eXoZymes stock FAQ
What is eXoZymes's stock price today?
EXOZ last traded at $2.91 as of Nov 20, 4:00 PM EST, down 14.05% on the day. Prices are delayed at least 15 minutes.
Who is eXoZymes's CEO?
Mr. Michael Heltzen is the chief executive officer of eXoZymes Inc., which has about 32 employees.
What is the EXOZ 52-week high?
The 52-week high for EXOZ is $16.16 and the 52-week low is $2.81. The stock is currently 82.0% below its high.